Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

Cited In for PubMed (Select 17386981)

1.

Massage Impact on Pain in Opioid-dependent Patients in Substance Use Treatment.

Wiest KL, Asphaug VJ, Carr KE, Gowen EA, Hartnett TT.

Int J Ther Massage Bodywork. 2015 Mar 1;8(1):12-24. eCollection 2015 Mar.

2.

Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance.

Dhingra L, Perlman DC, Masson C, Chen J, McKnight C, Jordan AE, Wasser T, Portenoy RK, Cheatle MD.

Drug Alcohol Depend. 2015 Apr 1;149:285-9. doi: 10.1016/j.drugalcdep.2015.02.007. Epub 2015 Feb 17.

PMID:
25735466
3.

Chronic Pain and DepressionAmong Primary Care Patients Treated with Buprenorphine.

Stein MD, Herman DS, Bailey GL, Straus J, Anderson BJ, Uebelacker LA, Weisberg RB.

J Gen Intern Med. 2015 Jul;30(7):935-41. doi: 10.1007/s11606-015-3212-y. Epub 2015 Feb 13.

PMID:
25678375
4.

Data Sources Regarding the Nonmedical Use of Pharmaceutical Opioids in the United States.

Schmidt T, Zimam A, Nielsen A, Wakeland W.

Rev Health Care. 2014;5(1):33-50.

5.

Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.

Meyer AC, Miller ME, Sigmon SC.

Addict Behav. 2015 Mar;42:189-93. doi: 10.1016/j.addbeh.2014.11.006. Epub 2014 Nov 18.

PMID:
25481453
6.

Urban vs. rural differences in prescription opioid misuse among adults in the United States: informing region specific drug policies and interventions.

Rigg KK, Monnat SM.

Int J Drug Policy. 2015 May;26(5):484-91. doi: 10.1016/j.drugpo.2014.10.001. Epub 2014 Oct 23.

7.

Pain and emotional distress among substance-use patients beginning treatment relative to a representative comparison group.

Wiest KL, Colditz JB, Carr K, Asphaug VJ, McCarty D, Pilkonis PA.

J Addict Med. 2014 Nov-Dec;8(6):407-14. doi: 10.1097/ADM.0000000000000072.

PMID:
25275876
8.

Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City.

Mateu-Gelabert P, Guarino H, Jessell L, Teper A.

J Subst Abuse Treat. 2015 Jan;48(1):13-20. doi: 10.1016/j.jsat.2014.07.002. Epub 2014 Jul 11.

PMID:
25124258
9.

Sources of pharmaceutical opioids for non-medical use among young adults.

Daniulaityte R, Falck R, Carlson RG.

J Psychoactive Drugs. 2014 Jul-Aug;46(3):198-207. doi: 10.1080/02791072.2014.916833.

10.

Advancing the field of pharmaceutical risk minimization through application of implementation science best practices.

Smith MY, Morrato E.

Drug Saf. 2014 Aug;37(8):569-80. doi: 10.1007/s40264-014-0197-0.

11.

"Nonmedical" prescription opioid use in North America: a call for priority action.

Voon P, Kerr T.

Subst Abuse Treat Prev Policy. 2013 Dec 1;8:39. doi: 10.1186/1747-597X-8-39.

12.

A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn JR, Higgins ST.

JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 10.1001/jamapsychiatry.2013.2216.

13.

Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.

Lofwall MR, Babalonis S, Nuzzo PA, Siegel A, Campbell C, Walsh SL.

Drug Alcohol Depend. 2013 Nov 1;133(1):188-97. doi: 10.1016/j.drugalcdep.2013.05.010. Epub 2013 Jun 4.

14.

Engagement, retention, and abstinence for three types of opioid users in Florida.

McCabe BE, Santisteban DA, Mena MP, Duchene DM, McLean C, Monroe M.

Subst Use Misuse. 2013 Jun;48(8):623-34. doi: 10.3109/10826084.2013.800112. Epub 2013 Jun 10.

15.

Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W.

J Stud Alcohol Drugs. 2013 Jul;74(4):605-13.

16.

Diversion of benzodiazepines through healthcare sources.

IbaƱez GE, Levi-Minzi MA, Rigg KK, Mooss AD.

J Psychoactive Drugs. 2013 Jan-Mar;45(1):48-56.

17.

Understanding the etiology of prescription opioid abuse: implications for prevention and treatment.

Rigg KK, Murphy JW.

Qual Health Res. 2013 Jul;23(7):963-75. doi: 10.1177/1049732313488837. Epub 2013 May 8.

18.

Early experience with electronic prescribing of controlled substances in a community setting.

Thomas CP, Kim M, Kelleher SJ, Nikitin RV, Kreiner PW, McDonald A, Carrow GM.

J Am Med Inform Assoc. 2013 Jun;20(e1):e44-51. doi: 10.1136/amiajnl-2012-001499. Epub 2013 Apr 5.

19.

Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy.

Petry NM, Carroll KM.

Psychol Addict Behav. 2013 Dec;27(4):1036-43. doi: 10.1037/a0032175. Epub 2013 Mar 25.

20.

Collaboration or coercion? Partnering to divert prescription opioid medications.

Green TC, Bowman SE, Ray M, Zaller N, Heimer R, Case P.

J Urban Health. 2013 Aug;90(4):758-67. doi: 10.1007/s11524-012-9784-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk